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savings provide the opportunity for a more individualized
therapy in those schizophrenic patients who are in need of and
without budget overspend.
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OBJECTIVES: 1) To assess cost-utility of sertindole (Serdolect®)
compared with commonly used antipsychotic drugs in
Poland—haloperidol and risperidone in the treatment of schizo-
phrenia, and 2) To assess the ﬁnancial consequences of sertindole
reimbursement for Polish National Health Fund (NHF)
budget.—haloperidol and risperidone in the treatment of schizo-
phrenia, and 2) To assess the ﬁnancial consequences of sertindole
reimbursement for Polish National Health Fund (NHF) budget.
METHODS: Cost-utility decision model comparing three phar-
macotherapy strategies in the treatment of chronic schizophrenia
(sertindole, risperidone, haloperidol) was developed. Payer per-
spective for health services (NHF budget and patient) and one-
year time horizon were undertaken. Measure of effectiveness was
expressed in quality adjusted life years (QALYs). Data on clinical
efﬁcacy based on published literature. Main parameters of the
model were: compliance, clinical response, recurrence, adverse
events, cost parameters (eg. drugs, AEs, treatment in hospital and
outpatient setting, GP) and disutilities associated with AEs and
relapse. Budget impact analysis was performed in a 5-year
horizon following Serdolect® introduction. RESULTS: In one-
year horizon, incremental cost of QALY saved (ICER) was:
PLN14,117 (sertindole vs. risperidone) and PLN56,044 (sertin-
dole vs haloperidol). The sensitivity analyses showed the robust-
ness of the results. Based on ﬁve year budget forecast, public
payer expenditures on atypical antipsychotic drugs would
increase by 0.005% (PLN13,478) in year one and by 0.118%
(PLN402,243) in year ﬁve of Serdolect® reimbursement. CON-
CLUSIONS: ICERs indicate that sertindole is a cost-effective
strategy compared to risperidone and haloperidol in the treat-
ment of chronic schizophrenia in Poland. Reimbursement of
Serdolect® would result in a minor increase in Polish NHF
expenditures. Reimbursement of Serdolect® would result in a
minor increase in Polish NHF expenditures.
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OBJECTIVES: Compare the cost-effectiveness of quetiapine
extended-release versus olanzapine, in patients with ﬁrst episode
schizophrenia who have failed on generic risperidone.
METHODS: A one-year, decision analytic model populated with
appropriate published efﬁcacy data together with drug acquisi-
tion and resource use costs, was employed to illustrate the pos-
sible consequences of treatment with generic risperidone
followed by either olanzapine or quetiapine extended-release.
The perspective taken was that of the UK National Health
Service. The clinical outcomes measured and compared were:
discontinuation due to clinical reasons; response; relapse;
number of patients effectively managed; and those requiring
further intervention. An assumption was made that quetiapine
extended-release would deliver the same outcomes as the instant-
release formulation in this population. The doses applied (ris-
peridone 3.3mg, olanzapine 15.7mg and quetiapine extended-
release 646 mg) were the mean doses observed in the clinical
trials. RESULTS: Relative to olanzapine more patients were
effectively managed on quetiapine (5%). The total cost per effec-
tively managed patient was estimated to be higher for olanzapine
compared to quetiapine (£21,658 and £20,955 respectively).
Quetiapine also had fewer patients that: discontinued due to
clinical reasons; failed to respond; relapsed; or required addi-
tional intervention relative to olanzapine (28%, 5%, 9% and
13% respectively). CONCLUSIONS: Not all atypical-naive
patients that receive generic risperidone will tolerate or respond
adequately to therapy and for those patients that require subse-
quent treatment with an atypical antipsychotic, quetiapine
extended-release is a cost-effective second-line treatment choice
compared to olanzapine. The analysis is limited by the lack of
comparative data in this population. The effectiveness of que-
tiapine extended-release was assumed to be the same as the
instant-release formulation, however, due to a less complicated
and shorter titration regimen allowing therapeutic dose to be
reached much sooner, quetiapine extended-release may have
added beneﬁt via a positive impact on patient compliance and
psychosis management.
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OBJECTIVES: To assess the cost-effectiveness of quetiapine
(QTP) in combination with lithium (Li) or divalproex (DVP)
(QTP+Li/DVP) in comparison with placebo in combination with
lithium or divalproex (Li/DVP alone) in the maintenance treat-
ment of bipolar I disorder. METHODS: A Markov decision-
analytic model was developed to estimate the relative costs and
outcomes associated with QTP+Li/DVP compared with Li/DVP
alone from the perspective of the UK National Health Service.
Model parameters and transition probabilities were derived from
2 identical randomized, double-blind clinical trials of up to 104
weeks’ duration and with a combined ITT patient population of
1326 (Trials 126 and 127). The Markov model followed, over 2
years, 1000 hypothetical patients (receiving either QTP+Li/DVP
or Li/DVP alone) with bipolar I disorder in remission, where each
patient could move through 1 of 4 mood states (euthymia,
mania, depression, or no active therapy) through 8 quarterly
cycles. During each cycle, a patient accumulated costs and out-
comes and faced a probability of transitioning to another mood
state. The reference year was 2007 and the discount rate was
3.5%. RESULTS: Compared with Li/DVP alone, QTP+Li/DVP
signiﬁcantly reduced the number of acute mood events per
patient per year from 0.92 to 0.42 with an ICER of £506 per
acute mood event averted. QTP+Li/DVP was also associated
with reductions of 54% and 55% in rates of acute mania and
depression events, a 25% reduction in hospitalizations related to
acute mania, and a 38% reduction in hospitalizations related to
acute depression, all leading to a 29% reduction in hospitaliza-
tion costs. The incremental cost per QALY gained for QTP+Li/
DVP treatment was £7453. Sensitivity analyses found the results
to be robust. CONCLUSIONS: QTP+Li/DVP is cost-effective
and has potential beneﬁts derived from reduced hospitalizations
associated with acute mood events, compared with Li/DVP
alone.
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